Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has issued an announcement.
Zhaoke Ophthalmology Limited has announced a distribution agreement with AFT Pharmaceuticals to commercialize BRIMOCHOL PF in Australia and New Zealand. BRIMOCHOL PF is an eye drop aimed at treating presbyopia, a common age-related vision problem, and has shown promising Phase 3 trial results. This agreement allows AFT exclusive rights to market and distribute the product, potentially enhancing Zhaoke’s market presence in the Asia-Pacific region and offering a novel therapeutic option where few exist.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on developing innovative ophthalmic treatments, particularly in the eye care industry. They are collaborating with global biotech companies like Tenpoint Therapeutics to create groundbreaking solutions for vision issues related to aging.
YTD Price Performance: 9.17%
Average Trading Volume: 682,636
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$715.4M
For detailed information about 6622 stock, go to TipRanks’ Stock Analysis page.
